PT - JOURNAL ARTICLE AU - C. McNamara AU - G. Sugrue AU - B. Murray AU - P.J. MacMahon TI - Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2—Surveillance for Treatment Complications and Disease Progression AID - 10.3174/ajnr.A5148 DP - 2017 Sep 01 TA - American Journal of Neuroradiology PG - 1672--1680 VI - 38 IP - 9 4099 - http://www.ajnr.org/content/38/9/1672.short 4100 - http://www.ajnr.org/content/38/9/1672.full SO - Am. J. Neuroradiol.2017 Sep 01; 38 AB - SUMMARY: An understanding of the new generation of MS drugs in conjunction with the key role MR imaging plays in the detection of disease progression, opportunistic infections, and drug-related adverse effects is of vital importance to the neuroradiologist. Part 1 of this review outlined the current treatment options available for MS and examined the mechanisms of action of the various medications. It also covered specific complications associated with each form of therapy. Part 2, in turn deals with the subject of pharmacovigilance and the optimal frequency of MRI monitoring for each individual patient, depending on his or her unique risk profile. Special attention is given to the diagnosing of progressive multifocal leukoencephalopathy in patients treated with natalizumab as this is a key area in which neuroradiologists can contribute to improved patient outcomes. This article also outlines the aims of treatment and reviews the possibility of “no evidence of disease activity” becoming a treatment goal with the availability of more effective therapies. Potential future areas and technologies including image subtraction, brain volume measurement and advanced imaging techniques such as double inversion recovery are also reviewed. It is anticipated that such advancements in this rapidly developing field will improve the accuracy of monitoring an individual patient's response to treatment.BVbrain volumeDIRdouble inversion recoveryDMTdisease-modifying therapyIRISimmune reconstitution inflammatory syndromeJC virusJohn Cunningham virusMTRmagnetization transfer ratioNEDAno evidence of disease activityNTZnatalizumabNTZ PMLnatalizumab-associated PMLPMLprogressive multifocal leukoencephalopathyPML IRISPML-associated IRISPSIRphase-sensitive inversion recovery